Patent Law Weblog
recent posts
- Moderna Settles Patent Litigation with Arbutus et al.
- USPTO and DOJ Statement of Interest in Collision Communications: Another Thumb on the Scale in Favor of NPE Patent Plaintiffs
- Oasis Tooling, Inc. v. Siemens Industry Software Inc. (Fed. Cir. 2026)
- Why AI Will Not Take Over the World
- BioNTech Sues Moderna over mRNA Vaccine Technology
about
Category: Patent Litigation
-
By Suresh Pillai — The Medicines Company Files New Lawsuits in Angiomax® Patent Dispute Following up on lawsuits filed in October against defendant Teva Pharmaceuticals, The Medicines Company has now filed new lawsuits alleging infringement of U.S. Patent No. 7,598,343, which covers The Medicines Company's blood thinning drug, Angiomax®. In its original suit, The…
-
By Kevin E. Noonan — The latest challenge to Amgen's erythropoietin (EPO) franchise ended today, when Hoffman-La Roche agreed to keep its pegylated derivative of human EPO, Mircera®, off the market until July 1, 2014. The U.S. Food and Drug Administration granted approval for Roche to market Mircera® in November, 2007 (it has already…
-
By Suresh Pillai — Teva's Discovery Request Blocked in Aricept® Suit The U.S. District Court for the District of New Jersey has denied a discovery request by Teva Pharmaceutical Industries to examine communications between Eisai and the U.S. Patent and Trademark Office. Eisai filed the original suit in 2005 following Teva's submission of an…
-
By Suresh Pillai — Breach of Contract Claims Dismissed in AIA-Mayo Suit The District Court for the Middle District of Florida has dismissed two claims brought by the Alzheimer's Institute of America (AIA) against the Mayo Clinic and Myriad Pharmaceuticals alleging that the defendants had breached the no-challenge clause contained within the institutional licensing…
-
By Suresh Pillai — Exela Files Appeal to Alphagan® Decision Following a ruling by the U.S. District Court for the District of Delaware that Exela PharmSci's proposed generic version of Allergan's Alphagan® glaucoma treatment infringed an Allergan patent, Exela has filed a notice of appeal, seeking to have the District Court's decision reviewed by…
-
By Suresh Pillai — Infosint Seeks Increased Damages Award in Citalopram Suit Following a decision by the U.S. District Court for the Southern District of New York in October finding Forest Laboratories and Lundbeck A/S liable for infringement of Infosint's patent covering the antidepressant citalopram, Infosint has now returned to the District Court seeking…
-
By Suresh Pillai — Mayo Seeks Supreme Court Review in Prometheus Labs Case Following the U.S. Court of Appeals for the Federal Circuit's ruling that Prometheus Laboratories' method patents were valid under In re Bilski, the Mayo Clinic has petitioned the U.S. Supreme Court to review the ruling. The patents-in-suit, U.S. Patent Nos. 6,355,623…
-
By Suresh Pillai — Teva Loses Bid For Dismissal of Famciclovir Infringement Suit Last week, the U.S. District Court for the District of New Jersey denied Teva Pharmaceutical's bid to have Novartis Pharmaceuticals' patent infringement suit dismissed for lack of plaintiff standing. Novartis and two of its subsidiaries filed the original lawsuit in 2005…
-
By Suresh Pillai — Infosint Awarded $15 Million Verdict in Lexapro® Suit A federal jury in the U.S. District Court for the Southern District of New York has awarded Infosint $15 million as a reasonable royalty in Infosint's patent dispute with Lundbeck A/S and Forest Laboratories, Inc. over the patent covering Lexapro®. The patent-in-suit,…
-
By Suresh Pillai — Teva Files Counterclaims in Gilead Suit In answer to a complaint filed in the U.S. District Court for the Southern District of New York by Gilead Sciences Inc. over alleged patent infringement, Teva Pharmaceuticals has filed an amended answer and counterclaim alleging that the patents-in-suit are invalid. The patents-in-suit, U.S.…
Patent Docs 